NervGen Pharma Corp. (NGEN.V)

CAD 2.46

(-7.17%)

Total Liabilities Summary of NervGen Pharma Corp.

NervGen Pharma Corp.'s latest annual total liabilities in 2023 was 15.24 Million CAD , up 46.39% from previous year.
NervGen Pharma Corp.'s latest quarterly total liabilities in 2024 Q2 was 15.39 Million CAD , up 18.84% from previous quarter.
NervGen Pharma Corp. reported annual total liabilities of 10.41 Million CAD in 2022, up 865.99% from previous year.
NervGen Pharma Corp. reported annual total liabilities of 1.07 Million CAD in 2021, up 42.78% from previous year.
NervGen Pharma Corp. reported quarterly total liabilities of 15.39 Million CAD for 2024 Q2, up 18.84% from previous quarter.
NervGen Pharma Corp. reported quarterly total liabilities of 15.24 Million CAD for 2023 FY, up 46.39% from previous quarter.

Annual Total Liabilities Chart of NervGen Pharma Corp. (2023 - 2017)

Historical Annual Total Liabilities of NervGen Pharma Corp. (2023 - 2017)

Year	Total Liabilities	Total Liabilities Growth
2023	15.24 Million CAD	46.39%
2022	10.41 Million CAD	865.99%
2021	1.07 Million CAD	42.78%
2020	755.07 Thousand CAD	-18.28%
2019	923.94 Thousand CAD	58.45%
2018	583.1 Thousand CAD	513.4%
2017	95.06 Thousand CAD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	12.95 Million CAD	-15.0%
2024 Q2	15.39 Million CAD	18.84%
2023 FY	15.24 Million CAD	46.39%
2023 Q3	11.25 Million CAD	14.17%
2023 Q1	9.21 Million CAD	-11.47%
2023 Q2	9.85 Million CAD	6.9%
2023 Q4	15.24 Million CAD	35.48%
2022 Q1	1.11 Million CAD	3.83%
2022 FY	10.41 Million CAD	865.99%
2022 Q2	3.1 Million CAD	177.59%
2022 Q4	10.41 Million CAD	-0.53%
2022 Q3	10.46 Million CAD	236.93%
2021 Q1	1.15 Million CAD	53.44%
2021 FY	1.07 Million CAD	42.78%
2021 Q4	1.07 Million CAD	-0.63%
2021 Q3	1.08 Million CAD	7.28%
2021 Q2	1.01 Million CAD	-12.71%
2020 FY	755.07 Thousand CAD	-18.28%
2020 Q2	547.48 Thousand CAD	-24.75%
2020 Q4	755.07 Thousand CAD	133.4%
2020 Q3	323.51 Thousand CAD	-40.91%
2020 Q1	727.55 Thousand CAD	-21.26%
2019 Q1	474.34 Thousand CAD	-18.65%
2019 FY	923.94 Thousand CAD	58.45%
2019 Q4	923.94 Thousand CAD	61.09%
2019 Q3	573.54 Thousand CAD	75.25%
2019 Q2	327.26 Thousand CAD	-31.01%
2018 FY	583.1 Thousand CAD	513.4%
2018 Q4	583.1 Thousand CAD	0.0%
2017 FY	95.06 Thousand CAD	0.0%

Peer Total Liabilities Comparison of NervGen Pharma Corp.

Name	Total Liabilities	Total Liabilities Difference
Arch Biopartners Inc.	6.68 Million CAD	-128.187%
Covalon Technologies Ltd.	6.1 Million CAD	-149.602%
Hemostemix Inc.	7.68 Million CAD	-98.375%
Universal Ibogaine Inc.	2.37 Million CAD	-541.99%
Kane Biotech Inc.	14.09 Million CAD	-8.196%
MedMira Inc.	18.68 Million CAD	18.403%
Marvel Biosciences Corp.	2.39 Million CAD	-537.211%
XORTX Therapeutics Inc.	1.08 Million CAD	-1299.816%